Overview

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis

Status:
Active, not recruiting
Trial end date:
2025-06-11
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).
Phase:
Phase 3
Details
Lead Sponsor:
UCB Biopharma SRL